|
rs113488022
|
|
Colorectal Carcinoma
|
|
0.900 |
GeneticVariation
|
BEFREE |
Current clinical guidelines recommend mutation analysis for select codons in KRAS and NRAS exons 2, 3, and 4 and BRAF V600E to guide therapy selection and prognostic stratification in advanced colorectal cancer.
|
31589789 |
2020 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
PA and GG BRAF V600E-mutant had significantly lower rADCmean (p < 0.001) and rADCmin (p < 0.001) values than wild type, regardless of tumor histology and location.
|
31667545 |
2020 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Half of the tumors in our patient cohort were V600-wildtype and half were V600E mutant.All tumors expressed PD-L1.
|
31819973 |
2020 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
While under normoxic conditions the expression of glycolysis-related genes showed no correlation with origin or BRAF mutation status, GLUT1 expression was significantly elevated in metastatic and BRAF-V600E mutated melanoma cell lines under hypoxic conditions.
|
31791701 |
2020 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The p.V600E mutation in the BRAF protein is the most frequent mutation in cutaneous melanoma and is a recurrent alteration found in common benign naevi.
|
31102256 |
2020 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
We then knocked a mutation into BRAF encoding the V600E substitution and overexpressed the GREM1 transgene; the organoids were transplanted into colons of NOG mice and growth of xenograft tumors was measured.
|
31622618 |
2020 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
A 39-year-old white male was treated with vemurafenib, cobimetinib, and atezolizumab for a stage IV (T0, N3, M1) BRAF-V600E mutated malignant melanoma in the context of a clinical trial.
|
31157737 |
2020 |
|
rs113488022
|
|
Cutaneous Melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The p.V600E mutation in the BRAF protein is the most frequent mutation in cutaneous melanoma and is a recurrent alteration found in common benign naevi.
|
31102256 |
2020 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAF V600E/K mutant melanoma.
|
31796433 |
2020 |
|
rs113488022
|
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The V600E mutation of BRAF (BRAF<sup>V600E</sup>), which constitutively activates the ERK/MAPK signaling pathway, is frequently found in melanoma and other cancers.
|
31548614 |
2020 |
|
rs113488022
|
|
Papillary Thyroid Microcarcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E differentiates the recurrence risk of PTMC, particularly low-risk PTMC.
|
31790974 |
2020 |
|
rs113488022
|
|
Childhood Ganglioglioma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Role of diffusion weighted imaging for differentiating cerebral pilocytic astrocytoma and ganglioglioma BRAF V600E-mutant from wild type.
|
31667545 |
2020 |
|
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
A BRAF V600E mutation was identified in 15% of PD-L1-positive malignancies.
|
31821747 |
2020 |
|
rs113488022
|
|
Ganglioglioma
|
|
0.100 |
GeneticVariation
|
BEFREE |
PA and GG BRAF V600E-mutant had significantly lower rADCmean (p < 0.001) and rADCmin (p < 0.001) values than wild type, regardless of tumor histology and location.
|
31667545 |
2020 |
|
rs113488022
|
|
Childhood Pilocytic Astrocytoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Role of diffusion weighted imaging for differentiating cerebral pilocytic astrocytoma and ganglioglioma BRAF V600E-mutant from wild type.
|
31667545 |
2020 |
|
rs113488022
|
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Current clinical guidelines recommend mutation analysis for select codons in KRAS and NRAS exons 2, 3, and 4 and BRAF V600E to guide therapy selection and prognostic stratification in advanced colorectal cancer.
|
31589789 |
2020 |
|
rs113488022
|
|
Adult Pilocytic Astrocytoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Role of diffusion weighted imaging for differentiating cerebral pilocytic astrocytoma and ganglioglioma BRAF V600E-mutant from wild type.
|
31667545 |
2020 |
|
rs113488022
|
|
Glioma
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation is a distinctive genomic alteration of pediatric low-grade gliomas with prognostic and therapeutic implications.
|
31667545 |
2020 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thyroid neoplasms with PD-L1 expression also ae enriched with BRAF V600E mutations, suggesting that they are associated with more aggressive behavior.
|
31821747 |
2020 |
|
rs113488022
|
|
Pleomorphic Xanthoastrocytoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Review of histology showed malignant PXA with BRAF V600E mutation.
|
31748891 |
2020 |
|
rs113488022
|
|
Thyroid Nodule
|
|
0.100 |
GeneticVariation
|
BEFREE |
Testing for BRAF (V600E) Mutation in Thyroid Nodules with Fine-Needle Aspiration (FNA) Read as Suspicious for Malignancy (Bethesda V, Thy4, TIR4): a Systematic Review and Meta-analysis.
|
31811566 |
2020 |
|
rs113488022
|
|
Malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF- and MEK-targeted therapies are effective in BRAF V600E/K metastatic melanoma and lung cancers; however, responses are short-lived due to emergence of resistance.
|
31744895 |
2020 |
|
rs113488022
|
|
Metastatic melanoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Currently, several targeted therapy regimens are approved as first-line treatment in V600E/K-mutant advanced and metastatic melanoma.
|
31305324 |
2020 |
|
rs113488022
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF (V600E) mutation was found in about one in two nodules with thyroid FNA read as SFM, its PPV to detect cancers was excellent, and its NPV was very poor.
|
31811566 |
2020 |
|
rs113488022
|
|
Primary malignant neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Testing for BRAF (V600E) Mutation in Thyroid Nodules with Fine-Needle Aspiration (FNA) Read as Suspicious for Malignancy (Bethesda V, Thy4, TIR4): a Systematic Review and Meta-analysis.
|
31811566 |
2020 |